HC Wainwright Raises Earnings Estimates for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share estimates for shares of Biomea Fusion in a research report issued to clients and investors on Monday, June 23rd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.46) per share for the quarter, up from their prior estimate of ($0.66). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.

Several other equities analysts have also issued reports on BMEA. Piper Sandler assumed coverage on Biomea Fusion in a report on Tuesday, June 3rd. They issued an “overweight” rating and a $7.00 target price for the company. Oppenheimer set a $10.00 target price on Biomea Fusion in a report on Monday, March 24th. Barclays reduced their target price on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, April 2nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $16.00 target price on shares of Biomea Fusion in a report on Tuesday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $21.40.

Biomea Fusion Stock Up 3.2%

BMEA stock opened at $1.94 on Thursday. The firm has a market cap of $72.89 million, a PE ratio of -0.55 and a beta of -0.23. The business has a 50 day moving average of $1.93 and a 200-day moving average of $2.91. Biomea Fusion has a 12-month low of $1.29 and a 12-month high of $13.07.

Biomea Fusion (NASDAQ:BMEA) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.04.

Hedge Funds Weigh In On Biomea Fusion

Several institutional investors have recently bought and sold shares of BMEA. CWM LLC lifted its stake in Biomea Fusion by 8,058.5% in the first quarter. CWM LLC now owns 16,888 shares of the company’s stock valued at $36,000 after purchasing an additional 16,681 shares during the last quarter. Cerity Partners LLC purchased a new position in Biomea Fusion in the first quarter valued at approximately $37,000. Bayesian Capital Management LP purchased a new position in Biomea Fusion in the fourth quarter valued at approximately $42,000. Wells Fargo & Company MN lifted its stake in Biomea Fusion by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after purchasing an additional 4,399 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Biomea Fusion during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.